SCHEMBL7713294

SCHEMBL7713294

Cc1ccc(CC(NC(=O)OC(C)(C)C)c2ccc3c(c2)NC(=O)C(C)O3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.42
USP2 O75604 1/20 0.40
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 2/20 0.39
SMYD3 Q9H7B4 2/20 0.37
KMT2A Q03164 2/20 0.37
JAK2 O60674 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CCKAR P32238 1/20 0.37
CCKBR P32239 1/20 0.37
IDO1 P14902 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708144 0.92 PARP1 (0.42) PARP1TP53TSHRSMYD3KMT2A
SCHEMBL7713338 0.92 PARP1 (0.42) PARP1TP53POLBSMN1; SMN2TSHR
SCHEMBL7713374 0.92 PARP1 (0.50) PARP1TP53SMN1; SMN2TSHRKMT2A
SCHEMBL7711371 0.91 PARP1 (0.41) PARP1TP53SMN1; SMN2TSHRALDH1A1
SCHEMBL7708029 0.90 PARP1 (0.41) PARP1TP53SMN1; SMN2TSHRSMYD3
SCHEMBL7095640 0.90 ALDH1A1 (0.37) USP2GAATP53POLBSMN1; SMN2
SCHEMBL7708221 0.90 PARP1 (0.40) PARP1TP53SMN1; SMN2TSHRSMYD3
SCHEMBL7713423 0.89 PARP1 (0.41) PARP1TP53POLBSMN1; SMN2TSHR
SCHEMBL7710382 0.88 PARP1 (0.40) PARP1GAAPOLBSMN1; SMN2SMYD3
SCHEMBL7713251 0.86 CTSS (0.45) PARP1TP53POLBSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed